{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:08:13Z","timestamp":1777039693940,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaceclinicalcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Clinical Case Reports"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.aace.2021.07.001","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T12:20:50Z","timestamp":1626092450000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism"],"prefix":"10.1016","volume":"8","author":[{"given":"John C.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas G.","family":"Moraitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K.","family":"Belanoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"47","key":"10.1016\/j.aace.2021.07.001_bib1","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.aace.2021.07.001_bib2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.aace.2021.07.001_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"issue":"6","key":"10.1016\/j.aace.2021.07.001_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/eje.0.1490543","article-title":"Hepatic steatosis in Cushing\u2019s syndrome: a radiological assessment using computed tomography","volume":"149","author":"Rockall","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.aace.2021.07.001_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jsbmb.2015.07.020","article-title":"Glucocorticoids and non-alcoholic fatty liver disease","volume":"154","author":"Woods","year":"2015","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"12","key":"10.1016\/j.aace.2021.07.001_bib6","first-page":"3925","article-title":"Selective glucocorticoid receptor modulation prevents and reverses nonalcoholic fatty liver disease in male mice","volume":"159","author":"Koorneef","year":"2018","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.aace.2021.07.001_bib7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/ijo.2016.13","article-title":"A\u00a0novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet","volume":"40","author":"Mammi","year":"2016","journal-title":"Int J Obes"},{"key":"10.1016\/j.aace.2021.07.001_bib8","first-page":"6161348","article-title":"Effects of mifepristone on nonalcoholic fatty liver disease in a patient with a cortisol-secreting adrenal adenoma","volume":"2017","author":"Ragucci","year":"2017","journal-title":"Case Rep Endocrinol"},{"issue":"4","key":"10.1016\/j.aace.2021.07.001_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3350\/cmh.2017.0042","article-title":"Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"10.1016\/j.aace.2021.07.001_bib10","doi-asserted-by":"crossref","first-page":"W320","DOI":"10.2214\/AJR.07.2123","article-title":"Interobserver and intraobserver variability in the sonographic assessment of fatty liver","volume":"189","author":"Strauss","year":"2007","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.aace.2021.07.001_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1210\/me.2014-1062","article-title":"Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues","volume":"28","author":"Patel","year":"2014","journal-title":"Mol Endocrinol"},{"issue":"11","key":"10.1016\/j.aace.2021.07.001_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079724","article-title":"Mifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesity","volume":"8","author":"Hashimoto","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.aace.2021.07.001_bib13","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.aace.2021.07.001_bib14","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.aace.2021.07.001_bib15","doi-asserted-by":"crossref","first-page":"G760","DOI":"10.1152\/ajpgi.00030.2014","article-title":"Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with type 2 diabetes with and without fatty liver","volume":"307","author":"Macfarlane","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"10","key":"10.1016\/j.aace.2021.07.001_bib16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12325-009-0070-1","article-title":"Mifepristone treatment of olanzapine-induced weight gain in healthy men","volume":"26","author":"Gross","year":"2009","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.aace.2021.07.001_bib17","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/oby.2010.51","article-title":"Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men","volume":"18","author":"Gross","year":"2010","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.aace.2021.07.001_bib18","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1210\/clinem\/dgab046","article-title":"Mifepristone improves adipose tissue insulin sensitivity in insulin resistant individuals","volume":"106","author":"Gubbi","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.aace.2021.07.001_bib19","unstructured":"MIFEPREX\u00ae (mifepristone) tablets, for oral use [prescribing information], Danco Laboratories LLC., 2016. Accessed June 7, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020687s020lbl.pdf"},{"key":"10.1016\/j.aace.2021.07.001_bib20","doi-asserted-by":"crossref","first-page":"662865","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["AACE Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060521000869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2376060521000869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:31:53Z","timestamp":1762497113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2376060521000869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2376060521000869"],"URL":"https:\/\/doi.org\/10.1016\/j.aace.2021.07.001","relation":{},"ISSN":["2376-0605"],"issn-type":[{"value":"2376-0605","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism","name":"articletitle","label":"Article Title"},{"value":"AACE Clinical Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aace.2021.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}